Stock PHVS PHARVARIS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
23.35 USD +2.55% Intraday chart for Pharvaris N.V. +21.87% -16.76%
04-15 Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating MT
04-12 Pharvaris Files Mixed Shelf MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating
MT
Pharvaris Files Mixed Shelf
MT
Pharvaris Narrows Q4 Net Loss; Hires New CFO
MT
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
GL
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
CI
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
AQ
Pharvaris N : Poster
PU
Pharvaris N : EGM Meeting Minutes
PU
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K
PU
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
GL
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
AQ
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
GL
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
AQ
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
GL
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
AQ
Pharvaris Announces Extraordinary Meeting of Shareholders
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. News Pharvaris N.V.